Nabla Bio utilizes biologically informed machine learning and experimental technologies to design antibodies with atomic precision, targeting complex disease mechanisms such as GPCRs and ion channels. The platform enhances drug manufacturability, safety, and efficacy by integrating AI-driven design with empirical measurement of human-relevant drug properties.
Funding
$37.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
+1Founders
Product
Problem
Designing antibodies for complex disease mechanisms like GPCRs and ion channels is challenging due to the limitations of traditional methods in achieving atomic-level precision and fully capturing human-relevant drug properties. This can lead to issues with manufacturability, safety, and efficacy in drug development.
Solution
Nabla Bio utilizes a platform that integrates biologically informed machine learning with experimental technologies to design antibodies with atomic precision. Their approach combines AI-driven design with empirical measurement of human-relevant drug properties, enhancing drug manufacturability, safety, and efficacy. By leveraging generative models, multiplexed screens, and protein characterization technologies, Nabla Bio aims to expand the universe of druggable targets, including challenging targets like GPCRs and ion channels. The platform's close integration of AI-guided design and wet-lab driven measurement enables the design of drugs with superior properties for diseases that are currently difficult to treat.
Target Audience
Nabla Bio's primary customers are pharmaceutical companies seeking to design drugs against complex disease targets and improve drug properties through AI-driven design and experimental validation.
Features
- Generative models for de novo antibody design with atomic precision.
- Multiplexed screens for high-throughput measurement of drug properties.
- Protein characterization technologies to assess human-relevant drug properties at scale.
- AI-driven design integrated with empirical measurement for enhanced drug manufacturability, safety, and efficacy.
- Focus on challenging disease targets, including GPCRs and ion channels.